PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30501868-2 2018 Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. Prednisone 105-115 MYC proto-oncogene, bHLH transcription factor Homo sapiens 177-180 23335369-1 2013 MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and rituximab (R)-CHOP treated patients. Prednisone 164-174 MYC proto-oncogene, bHLH transcription factor Homo sapiens 0-3 25073258-5 2013 Our patient showed a high dermal Ki-67 level and concomitant C-MYC/8q24 translocation, which may account for the aggressive clinical course and refractoriness to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Prednisone 216-226 MYC proto-oncogene, bHLH transcription factor Homo sapiens 61-66 29674626-3 2018 We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 196-206 MYC proto-oncogene, bHLH transcription factor Homo sapiens 97-100 28291124-2 2017 MYC, a transcriptional factor and oncoprotein, is overexpressed in a fraction of DLBCL and indicates poor prognosis and aggressive clinical course when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 228-238 MYC proto-oncogene, bHLH transcription factor Homo sapiens 0-3 25468432-3 2015 Molecular analyses support the concept that there is a biological continuum between BL and DLBCL that includes variable activity of MYC, an oncoprotein once thought to be only associated with BL, but now recognized as a major predictor of survival among patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 354-364 MYC proto-oncogene, bHLH transcription factor Homo sapiens 132-135 24719189-1 2014 This study aims to investigate the prognostic significance of the MYC protein expression in diffuse large B cell lymphoma (DLBCL) patients treated with RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 222-232 MYC proto-oncogene, bHLH transcription factor Homo sapiens 66-69 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Prednisone 147-157 MYC proto-oncogene, bHLH transcription factor Homo sapiens 25-28 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Prednisone 166-176 MYC proto-oncogene, bHLH transcription factor Homo sapiens 96-99 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 MYC proto-oncogene, bHLH transcription factor Homo sapiens 77-80 20498406-2 2010 The aim of this study was to determine the frequency of MYC translocations in DLBCL and their prognostic impact in the era of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (CHOP-R) therapy. Prednisone 174-184 MYC proto-oncogene, bHLH transcription factor Homo sapiens 56-59